The effect of berberine adjunctive treatment on glycolipid metabolism in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial.

Abstract

Previous studies have shown that berberine can improve metabolic disturbances in non-psychiatric patients, but no clinical research has been conducted in schizophrenia. This study was a randomized, double-blind, placebo-controlled clinical trial. Eligible patients diagnosed with schizophrenia were randomized to receive placebo or berberine (900mg/day) as an adjunctive treatment for eight weeks. Peripheral glycolipid metabolism parameters were measured at baseline, week 4, and week 8. Sixty-five patients were included, and forty-nine patients completed the 8-week trial. Berberine led to significant declines in total cholesterol, low-density lipoprotein cholesterol, fasting serum insulin, and insulin resistance(all p<0.05) compared with placebo. Baseline body mass index and serum prolactin concentration could predict the effect of berberine on insulin resistance. Berberine adjunctive treatment may reduce the risk of glycolipid metabolic disturbances in patients with schizophrenia.

• Authors: Meijuan Li, Ying Liu, Yuying Qiu, Jing Zhang, Yonghui Zhang, Yongping Zhao, Qiong Jia, Jie Li
• Journal: Psychiatry research (Psychiatry Res) Vol. 300 Pg. 113899 (06 2021) ISSN: 1872-7123 [Electronic] Ireland
• PMID: 33812218 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2021 Elsevier B.V. All rights reserved.

Chemical References

• Antipsychotic Agents
• Glycolipids
• Berberine

Topics

• Antipsychotic Agents (therapeutic use)
• Berberine (therapeutic use)
• Double-Blind Method
• Glycolipids (therapeutic use)
• Humans
• Schizophrenia (drug therapy)
• Treatment Outcome